{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:33:17Z","timestamp":1791923597393,"version":"4.3.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T00:00:00Z","timestamp":1491609600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s13760-017-0772-0","type":"journal-article","created":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T01:18:48Z","timestamp":1491614328000},"page":"623-633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Corticosteroids in the management of acute multiple sclerosis exacerbations"],"prefix":"10.1007","volume":"117","author":[{"name":"On behalf of the Belgian Study Group for Multiple Sclerosis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8174-2898","authenticated-orcid":false,"given":"I.","family":"Smets","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Van Deun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bohyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"van Pesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vanopdenbosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bissay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,8]]},"reference":[{"issue":"9648","key":"772_CR1","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A (2008) Multiple sclerosis. Lancet 372(9648):1502\u20131517. doi: 10.1016\/S0140-6736(08)61620-7","journal-title":"Lancet"},{"issue":"Pt 3","key":"772_CR2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/brain\/awl007","volume":"129","author":"C Confavreux","year":"2006","unstructured":"Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129(Pt 3):606\u2013616. doi: 10.1093\/brain\/awl007","journal-title":"Brain"},{"issue":"Pt 7","key":"772_CR3","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/brain\/awq118","volume":"133","author":"A Scalfari","year":"2010","unstructured":"Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC (2010) The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133(Pt 7):1914\u20131929. doi: 10.1093\/brain\/awq118","journal-title":"Brain"},{"issue":"4","key":"772_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.nurt.2007.07.008","volume":"4","author":"EM Frohman","year":"2007","unstructured":"Frohman EM, Shah A, Eggenberger E, Metz L, Zivadinov R, Stuve O (2007) Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. NeuroTherapeutics 4(4):618\u2013626. doi: 10.1016\/j.nurt.2007.07.008","journal-title":"NeuroTherapeutics"},{"issue":"1\u20132","key":"772_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.mce.2007.05.019","volume":"275","author":"C Stahn","year":"2007","unstructured":"Stahn C, Lowenberg M, Hommes DW, Buttgereit F (2007) Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 275(1\u20132):71\u201378. doi: 10.1016\/j.mce.2007.05.019","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"772_CR6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1191\/1352458505ms1190oa","volume":"11","author":"JS Sloka","year":"2005","unstructured":"Sloka JS, Stefanelli M (2005) The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 11(4):425\u2013432","journal-title":"Mult Scler"},{"issue":"1","key":"772_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1096\/fj.01-0245com","volume":"16","author":"J Galon","year":"2002","unstructured":"Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart-Bornstein M, O\u2019Shea JJ, Chrousos GP, Bornstein SR (2002) Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 16(1):61\u201371. doi: 10.1096\/fj.01-0245com","journal-title":"FASEB J"},{"issue":"5","key":"772_CR8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/jlb.60.5.563","volume":"60","author":"WY Almawi","year":"1996","unstructured":"Almawi WY, Beyhum HN, Rahme AA, Rieder MJ (1996) Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 60(5):563\u2013572","journal-title":"J Leukoc Biol"},{"issue":"1","key":"772_CR9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2249.2002.01725.x","volume":"127","author":"EM Martinez-Caceres","year":"2002","unstructured":"Martinez-Caceres EM, Barrau MA, Brieva L, Espejo C, Barbera N, Montalban X (2002) Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects. Clin Exp Immunol 127(1):165\u2013171","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"772_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O\u2019Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292\u2013302. doi: 10.1002\/ana.22366","journal-title":"Ann Neurol"},{"issue":"1","key":"772_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-510X(94)00248-M","volume":"129","author":"TC Guthrie","year":"1995","unstructured":"Guthrie TC, Nelson DA (1995) Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential. J Neurol Sci 129(1):1\u20138","journal-title":"J Neurol Sci"},{"issue":"7","key":"772_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1177\/1352458510367721","volume":"16","author":"MB D\u2019Hooghe","year":"2010","unstructured":"D\u2019Hooghe MB, Nagels G, Bissay V, De Keyser J (2010) Modifiable factors influencing relapses and disability in multiple sclerosis. Mult Scler 16(7):773\u2013785. doi: 10.1177\/1352458510367721","journal-title":"Mult Scler"},{"issue":"4","key":"772_CR13","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/01.wnl.0000233834.09743.3b","volume":"67","author":"J Correale","year":"2006","unstructured":"Correale J, Fiol M, Gilmore W (2006) The risk of relapses in multiple sclerosis during systemic infections. Neurology 67(4):652\u2013659. doi: 10.1212\/01.wnl.0000233834.09743.3b","journal-title":"Neurology"},{"issue":"7442","key":"772_CR14","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/bmj.38041.724421.55","volume":"328","author":"DC Mohr","year":"2004","unstructured":"Mohr DC, Hart SL, Julian L, Cox D, Pelletier D (2004) Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 328(7442):731. doi: 10.1136\/bmj.38041.724421.55","journal-title":"BMJ"},{"key":"772_CR15","doi-asserted-by":"publisher","first-page":"CD001331","DOI":"10.1002\/14651858.CD001331","volume":"4","author":"G Filippini","year":"2000","unstructured":"Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, Candelise L (2000) Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 4:CD001331. doi: 10.1002\/14651858.CD001331","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"772_CR16","first-page":"1","volume":"20","author":"AS Rose","year":"1970","unstructured":"Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW (1970) Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo\u2014final report. Neurology 20(5):1\u201359","journal-title":"Neurology"},{"issue":"6","key":"772_CR17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s004150070172","volume":"247","author":"F Brusaferri","year":"2000","unstructured":"Brusaferri F, Candelise L (2000) Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 247(6):435\u2013442","journal-title":"J Neurol"},{"issue":"4","key":"772_CR18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/135245850000600408","volume":"6","author":"DM Miller","year":"2000","unstructured":"Miller DM, Weinstock-Guttman B, Bethoux F, Lee JC, Beck G, Block V, Durelli L, LaMantia L, Barnes D, Sellebjerg F, Rudick RA (2000) A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler 6(4):267\u2013273","journal-title":"Mult Scler"},{"issue":"1","key":"772_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1352458515590648","volume":"22","author":"C Ramo-Tello","year":"2016","unstructured":"Ramo-Tello C, Tintore M, Rovira A, Ramio-Torrenta L, Brieva L, Saiz A, Cano A, Carmona O, Hervas JV, Grau-Lopez L (2016) Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses. Mult Scler 22(1):117\u2013121. doi: 10.1177\/1352458515590648","journal-title":"Mult Scler"},{"issue":"9","key":"772_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"RW Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326(9):581\u2013588. doi: 10.1056\/NEJM199202273260901","journal-title":"N Engl J Med"},{"issue":"24","key":"772_CR21","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1056\/NEJM199312093292403","volume":"329","author":"RW Beck","year":"1993","unstructured":"Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 329(24):1764\u20131769. doi: 10.1056\/NEJM199312093292403","journal-title":"N Engl J Med"},{"issue":"2","key":"772_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000069408","volume":"18","author":"DS Goodin","year":"1999","unstructured":"Goodin DS (1999) Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology 18(2):53\u201363. doi: 10.1159\/000069408","journal-title":"Neuroepidemiology"},{"issue":"2","key":"772_CR23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1212\/WNL.51.2.529","volume":"51","author":"F Sellebjerg","year":"1998","unstructured":"Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J (1998) Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 51(2):529\u2013534","journal-title":"Neurology"},{"issue":"7212","key":"772_CR24","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0140-6736(61)91030-3","volume":"2","author":"H Miller","year":"1961","unstructured":"Miller H, Newell DJ, Ridley A (1961) Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (A.C.T.H.). Lancet 2(7212):1120\u20131122","journal-title":"Lancet"},{"issue":"2","key":"772_CR25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1212\/WNL.36.2.238","volume":"36","author":"L Durelli","year":"1986","unstructured":"Durelli L, Cocito D, Riccio A, Barile C, Bergamasco B, Baggio GF, Perla F, Delsedime M, Gusmaroli G, Bergamini L (1986) High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 36(2):238\u2013243","journal-title":"Neurology"},{"issue":"5","key":"772_CR26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jnnp.50.5.511","volume":"50","author":"NM Milligan","year":"1987","unstructured":"Milligan NM, Newcombe R, Compston DA (1987) A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 50(5):511\u2013516","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"772_CR27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0022-510X(97)00159-7","volume":"152","author":"SR Filipovic","year":"1997","unstructured":"Filipovic SR, Drulovic J, Stojsavljevic N, Levic Z (1997) The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis. J Neurol Sci 152(2):147\u2013153","journal-title":"J Neurol Sci"},{"issue":"4","key":"772_CR28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000117038","volume":"34","author":"L Mantia La","year":"1994","unstructured":"La Mantia L, Eoli M, Milanese C, Salmaggi A, Dufour A, Torri V (1994) Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. Eur Neurol 34(4):199\u2013203","journal-title":"Eur Neurol"},{"issue":"1","key":"772_CR29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000116368","volume":"29","author":"C Milanese","year":"1989","unstructured":"Milanese C, La Mantia L, Salmaggi A, Campi A, Eoli M, Scaioli V, Nespolo A, Corridori F (1989) Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Clinical, cerebrospinal fluid and neurophysiological results. Eur Neurol 29(1):10\u201314","journal-title":"Eur Neurol"},{"issue":"3","key":"772_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/eye.2008.25","volume":"23","author":"R Tandon","year":"2009","unstructured":"Tandon R, Verma K, Chawla B, Sharma N, Titiyal JS, Kalaivani M, Vajpayee RB (2009) Intravenous dexamethasone vs methylprednisolone pulse therapy in the treatment of acute endothelial graft rejection. Eye 23(3):635\u2013639. doi: 10.1038\/eye.2008.25","journal-title":"Eye"},{"issue":"7","key":"772_CR31","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1212\/WNL.39.7.969","volume":"39","author":"AJ Thompson","year":"1989","unstructured":"Thompson AJ, Kennard C, Swash M, Summers B, Yuill GM, Shepherd DI, Roche S, Perkin GD, Loizou LA, Ferner R et al (1989) Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 39(7):969\u2013971","journal-title":"Neurology"},{"key":"772_CR32","doi-asserted-by":"publisher","first-page":"CD006921","DOI":"10.1002\/14651858.CD006921.pub3","volume":"12","author":"JM Burton","year":"2012","unstructured":"Burton JM, O\u2019Connor PW, Hohol M, Beyene J (2012) Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 12:CD006921. doi: 10.1002\/14651858.CD006921.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"9997","key":"772_CR33","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S0140-6736(15)61137-0","volume":"386","author":"E Page Le","year":"2015","unstructured":"Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G, investigators C, West Network for Excellence in N (2015) Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 386(9997):974\u2013981. doi: 10.1016\/S0140-6736(15)61137-0","journal-title":"Lancet"},{"issue":"6","key":"772_CR34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/1352458513508835","volume":"20","author":"C Ramo-Tello","year":"2014","unstructured":"Ramo-Tello C, Grau-Lopez L, Tintore M, Rovira A, Ramio I, Torrenta L, Brieva L, Cano A, Carmona O, Saiz A, Torres F, Giner P, Nos C, Massuet A, Montalban X, Martinez-Caceres E, Costa J (2014) A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler 20(6):717\u2013725. doi: 10.1177\/1352458513508835","journal-title":"Mult Scler"},{"issue":"22","key":"772_CR35","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1212\/WNL.0b013e3181c3fd5b","volume":"73","author":"V Martinelli","year":"2009","unstructured":"Martinelli V, Rocca MA, Annovazzi P, Pulizzi A, Rodegher M, Martinelli Boneschi F, Scotti R, Falini A, Sormani MP, Comi G, Filippi M (2009) A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology 73(22):1842\u20131848. doi: 10.1212\/WNL.0b013e3181c3fd5b","journal-title":"Neurology"},{"issue":"6","key":"772_CR36","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1212\/01.WNL.0000138572.82125.F5","volume":"63","author":"SA Morrow","year":"2004","unstructured":"Morrow SA, Stoian CA, Dmitrovic J, Chan SC, Metz LM (2004) The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 63(6):1079\u20131080","journal-title":"Neurology"},{"issue":"5","key":"772_CR37","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1177\/1352458514546786","volume":"21","author":"L Grau-Lopez","year":"2015","unstructured":"Grau-Lopez L, Teniente-Serra A, Tintore M, Rovira A, Ramio-Torrenta L, Brieva L, Saiz A, Cano A, Carmona O, Hervas JV, Martinez-Caceres EM, Ramo-Tello C (2015) Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses. Mult Scler 21(5):646\u2013650. doi: 10.1177\/1352458514546786","journal-title":"Mult Scler"},{"issue":"9997","key":"772_CR38","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(15)00072-0","volume":"386","author":"G Comi","year":"2015","unstructured":"Comi G, Radaelli M (2015) Oral corticosteroids for multiple sclerosis relapse. Lancet 386(9997):937\u2013939. doi: 10.1016\/S0140-6736(15)00072-0","journal-title":"Lancet"},{"issue":"15","key":"772_CR39","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1212\/WNL.0000000000003113","volume":"87","author":"I Kister","year":"2016","unstructured":"Kister I, Corboy JR (2016) Reducing costs while enhancing quality of care in MS. Neurology 87(15):1617\u20131622. doi: 10.1212\/WNL.0000000000003113","journal-title":"Neurology"},{"issue":"11","key":"772_CR40","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/jnnp.56.11.1219","volume":"56","author":"SM Alam","year":"1993","unstructured":"Alam SM, Kyriakides T, Lawden M, Newman PK (1993) Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 56(11):1219\u20131220","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9056","key":"772_CR41","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0140-6736(96)06453-7","volume":"349","author":"D Barnes","year":"1997","unstructured":"Barnes D, Hughes RA, Morris RW, Wade-Jones O, Brown P, Britton T, Francis DA, Perkin GD, Rudge P, Swash M, Katifi H, Farmer S, Frankel J (1997) Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349(9056):902\u2013906","journal-title":"Lancet"},{"key":"772_CR42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12883-015-0450-x","volume":"15","author":"O Caster","year":"2015","unstructured":"Caster O, Edwards IR (2015) Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses. BMC Neurol 15:206. doi: 10.1186\/s12883-015-0450-x","journal-title":"BMC Neurol"},{"issue":"1","key":"772_CR43","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/BF03347855","volume":"19","author":"Z Levic","year":"1996","unstructured":"Levic Z, Micic D, Nikolic J, Stojisavljevic N, Sokic D, Jankovic S, Kendereski A, Mavra M (1996) Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test. J Endocrinol Invest 19(1):30\u201334. doi: 10.1007\/BF03347855","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"772_CR44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1191\/1352458504ms978sr","volume":"10","author":"LH Visser","year":"2004","unstructured":"Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL, Lenderink AW (2004) A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 10(1):89\u201391","journal-title":"Mult Scler"},{"issue":"1\u20132","key":"772_CR45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000109260","volume":"59","author":"G Iuliano","year":"2008","unstructured":"Iuliano G, Napoletano R, Esposito A (2008) Multiple sclerosis: relapses and timing of remissions. Eur Neurol 59(1\u20132):44\u201348. doi: 10.1159\/000109260","journal-title":"Eur Neurol"},{"issue":"3","key":"772_CR46","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","volume":"13","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TT Group (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13(3):247\u2013256. doi: 10.1016\/S1474-4422(13)70308-9","journal-title":"Lancet Neurol"},{"issue":"12","key":"772_CR47","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CS Investigators (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087\u20131097. doi: 10.1056\/NEJMoa1206328","journal-title":"N Engl J Med"},{"issue":"10","key":"772_CR48","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","volume":"7","author":"DD Mikol","year":"2008","unstructured":"Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B, Rs group (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the rebif vs glatiramer acetate in relapsing MS disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7(10):903\u2013914. doi: 10.1016\/S1474-4422(08)70200-X","journal-title":"Lancet Neurol"},{"issue":"9856","key":"772_CR49","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, Clinical and Medical Investigations (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819\u20131828. doi: 10.1016\/S0140-6736(12)61769-3","journal-title":"Lancet"},{"issue":"17","key":"772_CR50","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"CT Investigators","year":"2008","unstructured":"Investigators CT, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359(17):1786\u20131801. doi: 10.1056\/NEJMoa0802670","journal-title":"N Engl J Med"},{"issue":"9","key":"772_CR51","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, Investigators A (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899\u2013910. doi: 10.1056\/NEJMoa044397","journal-title":"N Engl J Med"},{"issue":"5","key":"772_CR52","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1177\/1352458513519840","volume":"20","author":"DH Miller","year":"2014","unstructured":"Miller DH, Fazekas F, Montalban X, Reingold SC, Trojano M (2014) Pregnancy, sex and hormonal factors in multiple sclerosis. Mult Scler 20(5):527\u2013536. doi: 10.1177\/1352458513519840","journal-title":"Mult Scler"},{"issue":"5","key":"772_CR53","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nrneurol.2015.53","volume":"11","author":"S Vukusic","year":"2015","unstructured":"Vukusic S, Marignier R (2015) Multiple sclerosis and pregnancy in the \u2018treatment era\u2019. Nat Rev Neurol 11(5):280\u2013289. doi: 10.1038\/nrneurol.2015.53","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"772_CR54","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1007\/s00415-012-6653-9","volume":"260","author":"MK Houtchens","year":"2013","unstructured":"Houtchens MK, Kolb CM (2013) Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol 260(5):1202\u20131214. doi: 10.1007\/s00415-012-6653-9","journal-title":"J Neurol"},{"issue":"2","key":"772_CR55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/jnnp.51.2.285","volume":"51","author":"PR Lyons","year":"1988","unstructured":"Lyons PR, Newman PK, Saunders M (1988) Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects. J Neurol Neurosurg Psychiatry 51(2):285\u2013287","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"772_CR56","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/gut.37.5.613","volume":"37","author":"M Carpani de Kaski","year":"1995","unstructured":"Carpani de Kaski M, Rentsch R, Levi S, Hodgson HJ (1995) Corticosteroids reduce regenerative repair of epithelium in experimental gastric ulcers. Gut 37(5):613\u2013616","journal-title":"Gut"},{"issue":"6828","key":"772_CR57","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/bmj.304.6828.655-a","volume":"304","author":"M Guslandi","year":"1992","unstructured":"Guslandi M, Tittobello A (1992) Steroid ulcers: a myth revisited. BMJ 304(6828):655\u2013656","journal-title":"BMJ"},{"issue":"4","key":"772_CR58","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.otc.2010.04.003","volume":"43","author":"DM Poetker","year":"2010","unstructured":"Poetker DM, Reh DD (2010) A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am 43(4):753\u2013768. doi: 10.1016\/j.otc.2010.04.003","journal-title":"Otolaryngol Clin North Am"},{"issue":"10","key":"772_CR59","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.4065\/81.10.1361","volume":"81","author":"TP Warrington","year":"2006","unstructured":"Warrington TP, Bostwick JM (2006) Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 81(10):1361\u20131367. doi: 10.4065\/81.10.1361","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"772_CR60","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1378\/chest.104.2.622","volume":"104","author":"AE McLuckie","year":"1993","unstructured":"McLuckie AE, Savage RW (1993) Atrial fibrillation following pulse methylprednisolone therapy in an adult. Chest 104(2):622\u2013623","journal-title":"Chest"},{"issue":"1","key":"772_CR61","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1468-1331.2000.00026.x","volume":"7","author":"R Moretti","year":"2000","unstructured":"Moretti R, Torre P, Antonello RM, Zorzon M, Cazzato G (2000) Recurrent atrial fibrillation associated with pulse administration of high doses of methylprednysolone: a possible prophylactic treatment. Eur J Neurol 7(1):130","journal-title":"Eur J Neurol"},{"issue":"4","key":"772_CR62","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00228-013-1632-3","volume":"70","author":"O Caster","year":"2014","unstructured":"Caster O, Conforti A, Viola E, Edwards IR (2014) Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance. Eur J Clin Pharmacol 70(4):501\u2013503. doi: 10.1007\/s00228-013-1632-3","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"772_CR63","doi-asserted-by":"crossref","first-page":"656","DOI":"10.5812\/kowsar.1735143X.641","volume":"11","author":"K Gutkowski","year":"2011","unstructured":"Gutkowski K, Chwist A, Hartleb M (2011) Liver injury induced by high-dose methylprednisolone therapy: a case report and brief review of the literature. Hepat Mon 11(8):656\u2013661","journal-title":"Hepat Mon"},{"issue":"5","key":"772_CR64","first-page":"324","volume":"6","author":"MC Lopez-Serrano","year":"1996","unstructured":"Lopez-Serrano MC, Moreno-Ancillo A, Contreras J, Ortega N, Cabanas R, Barranco P, Munoz-Pereira M (1996) Two cases of specific adverse reactions to systemic corticosteroids. J Investig Allergol Clin Immunol 6(5):324\u2013327","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"772_CR65","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1191\/1352458503ms966oa","volume":"9","author":"S Tuzun","year":"2003","unstructured":"Tuzun S, Altintas A, Karacan I, Tangurek S, Saip S, Siva A (2003) Bone status in multiple sclerosis: beyond corticosteroids. Mult Scler 9(6):600\u2013604","journal-title":"Mult Scler"},{"issue":"7","key":"772_CR66","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1468-1331.2005.00988.x","volume":"12","author":"M Zorzon","year":"2005","unstructured":"Zorzon M, Zivadinov R, Locatelli L, Giuntini D, Toncic M, Bosco A, Nasuelli D, Bratina A, Tommasi MA, Rudick RA, Cazzato G (2005) Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 12(7):550\u2013556. doi: 10.1111\/j.1468-1331.2005.00988.x","journal-title":"Eur J Neurol"},{"issue":"6","key":"772_CR67","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s10072-011-0914-8","volume":"33","author":"MA Sahraian","year":"2012","unstructured":"Sahraian MA, Yadegari S, Azarpajouh R, Forughipour M (2012) Avascular necrosis of the femoral head in multiple sclerosis: report of five patients. Neurol Sci 33(6):1443\u20131446. doi: 10.1007\/s10072-011-0914-8","journal-title":"Neurol Sci"},{"issue":"8","key":"772_CR68","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-132-8-200004180-00005","volume":"132","author":"N Costedoat-Chalumeau","year":"2000","unstructured":"Costedoat-Chalumeau N, Amoura Z, Aymard G, Sevin O, Wechsler B, Cacoub P, Du LT, Diquet B, Ankri A, Piette JC (2000) Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone. Ann Intern Med 132(8):631\u2013635","journal-title":"Ann Intern Med"},{"issue":"12","key":"772_CR69","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1345\/aph.1H418","volume":"40","author":"KA Hazlewood","year":"2006","unstructured":"Hazlewood KA, Fugate SE, Harrison DL (2006) Effect of oral corticosteroids on chronic warfarin therapy. Ann Pharmacother 40(12):2101\u20132106. doi: 10.1345\/aph.1H418","journal-title":"Ann Pharmacother"},{"issue":"1","key":"772_CR70","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s002280050720","volume":"56","author":"T Varis","year":"2000","unstructured":"Varis T, Kivisto KT, Neuvonen PJ (2000) The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 56(1):57\u201360","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"772_CR71","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","volume":"46","author":"BG Weinshenker","year":"1999","unstructured":"Weinshenker BG, O\u2019Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46(6):878\u2013886","journal-title":"Ann Neurol"},{"issue":"5","key":"772_CR72","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1567-5688(09)71827-6","volume":"10","author":"R Klingel","year":"2009","unstructured":"Klingel R, Heibges A, Fassbender C (2009) Plasma exchange and immunoadsorption for autoimmune neurologic diseases\u2014current guidelines and future perspectives. Atheroscler Suppl 10(5):129\u2013132. doi: 10.1016\/S1567-5688(09)71827-6","journal-title":"Atheroscler Suppl"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-017-0772-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-017-0772-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-017-0772-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T16:24:43Z","timestamp":1568996683000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-017-0772-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,8]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["772"],"URL":"https:\/\/doi.org\/10.1007\/s13760-017-0772-0","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,8]]}}}